Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma

International Journal of Cancer

Volumn 82, Issue 6, 1999, Pages 837-845

  Van Hal, Nicole L W ^a   Van Dongen, Guus A M S ^a   Stigter Van Walsum, Marijke ^a   Snow, Gordon B ^a   Brakenhoff, Ruud H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; COMPLEMENTARY DNA;

ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; DNA LIBRARY; DOWN REGULATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ALTERNATIVE SPLICING; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; VARIATION (GENETICS);

EID: 0032817524     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990909)82:6<837::AID-IJC12>3.0.CO;2-H     Document Type: Article

References (24)

1. BRAKENHOFF, R.H., GERRETSEN, M., KNIPPELS, P.M.C., VAN DUK, M., VAN ESSEN, H., OLDE WEGHUIS, D., SINKE, R.J., SNOW, G.B. and VAN DONGEN, G.A.M.S., The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J. Cell Biol., 129, 1677-1689 (1995).
2. CAREY, T.E., WOLF, G.T., BAKER, S.R. and KRAUSE, C.J., Cell surface antigen expression and prognosis. In: W.E. Fee, H. Goepfert, M.E. Johns, E.W. Strong and P.M. Ward (eds.), Head and neck cancer, vol. 2, pp. 77-82, B.C. Decker, Philadelphia (1990).
3. DE BREE, R., ROOS, J.C., QUAK, J.J., DEN HOLLANDER, W., SNOW, G.B. and VAN DONGEN, G.A.M.S., Clinical screening of monoclonal antibodies 323/A3, cSF-25, and K928 for suitability of targeting tumors in the upper aerodigestive and respiratory tract. Nucl. Med. Commun., 15, 613-627 (1994).
4. 99mTc-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin. Cancer Res., 1, 591-598 (1995).
5. GAO, X., PORTER, A.T., GRIGNON, D.J., PONTES, J.E. and HONN, K.V., Diagnostic and prognostic markers for human prostate cancer. Prostate, 31, 264-281 (1997).
6. GÜNTHERT, U., HOFMANN, M., RUDY, W., REBER, S., ZÖLLER, M., HAUSSMANN, I., MATZKU, S., WENZEL, A., PONTA, H. and HERRLICH, P., A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65, 13-24 (1991).
7. HEIDER, K.-H., SPROLL, M., SUSANI, S., PATZELT, E., BEAUMIER, P., OSTERMANN, E., AHORN, H. and ADOLF, G.R., Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol. Immunother., 43, 245-253 (1996).
8. HOFMANN, M., RUDY, W., ZÖLLER, M., TÖLG, C., PONTA, H., HERRLICH, P. and GÜNTHERT, U., CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res., 51, 5292-5297 (1991).
9. HUDSON, D.L., SLEEMAN, J. and WATT, F.M., CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratinocytes and plays a role in intercellular adhesion. J. Cell Sci., 108, 1959-1970 (1995).
10. KAYA, G., RODRIGUEZ, I., JORCANO, J.L., VASSALLI, P. and STAMENKOVIC, I., Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Develop., 11, 996-1007 (1997).
11. KOOPMAN, G., HEIDER, K.-H., HORST, E., ADOLF, G.R., VAN DEN BERG, F., PONTA, H., HERRLICH, P. and PALS, S.T., Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J. exp. Med., 177, 897-904 (1993).
12. KUGELMAN, L.C., GANGULY, S., HAGGERTY, J.G., WEISSMAN, S.M. and MILSTONE, L.M., The core protein of epican, a heparan sulfate proteoglycan on keratinocytes, is an alternative form of CD44. J. invest. Dermatol., 99, 886-891 (1992).
13. MARTIAT, P., MAISIN, D., PHILIPPE, M., FERRANT, A., MICHAUX, J.L., CASSIMAN, J.J., VAN DEN BERGHE, H. and SOKAL, G., Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers. Br. J. Haematol., 75, 355-358 (1990).
14. MATSUMURA, Y. and TARIN, D., Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet, 340, 1053-1058 (1992).
15. MULDER, J.-W.R., KRUYT, P.M., SEWNATH, M., OOSTING, J., SELDENRIJK, C.A., WEIDEMA, W.F., OFFERHAUS, G.J.A. and PALS, S.T., Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet, 344, 1470-1472 (1994).
16. NORTHOVER, J., The use of prognostic markers in surgery for colorectal cancer. Europ. J. Cancer, 31A, 1207-1209 (1995).
17. ROYE, G.D., MYERS, R.B., BROWN, D., POCZATEK, R., BEENKEN, S.W. and GRIZZLE, W.E., CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus. Int. J. Cancer, 69, 254-258 (1996).
18. SALMI, M., GRÖN-VIRTA, K., SOINTU, P., GRENMAN, R., KALIMO, H. and JALKANEN, S., Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J. Cell Biol., 122, 431-442 (1993).
19. SCREATON, G.R., BELL, M.V., JACKSON, D.G., CORNELIS, F.B., GERTH, U. and BELL, J.I., Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. nat. Acad. Sci. (Wash.), 89, 12160-12164 (1992).
20. SHTIVELMAN, E. and BISHOP, J.M., Expression of CD44 is repressed in neuroblastoma cells. Mol. cell. Biol., 11, 5446-5453 (1991).
21. SOUKKA, T., SALMI, M., JOENSUU, H., HÄKKINEN, L., SOINTU, P., KOULU, L., KALIMO, K., KLEMI, P., GRÉNMAN, R. and JALKANEN, S., Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res., 57, 2281-2289 (1997).
22. STAUDER, R., EISTERER, W., THALER, J. and GÜNTHERT, U., CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood, 85, 2885-2899 (1995).
23. VAN HAL, N.L.W., VAN DONGEN, G.A.M.S., ROOD-KNIPPELS, E.M.C., VAN DER VALK, P., SNOW, G.B. and BRAKENHOFF, R.H., Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int. J. Cancer, 68, 520-527 (1996).
24. WIELENOA, V.J.M., HEIDER, K.-H., OFFERHAUS, G.J.A., ADOLF, G.R., VAN DEN BERG, F.M., PONTA, H., HERRLICH, P. and PALS. S.T., Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res., 53, 4754-4756 (1993).